Anterogen.Co.,Ltd. (KOSDAQ:065660)
 22,550
 +250 (1.12%)
  Oct 31, 2025, 3:30 PM KST
Anterogen.Co.,Ltd. Revenue
Anterogen.Co.,Ltd. had revenue of 1.89B KRW in the quarter ending June 30, 2025, with 10.40% growth. This brings the company's revenue in the last twelve months to 7.18B, up 7.84% year-over-year. In the year 2024, Anterogen.Co.,Ltd. had annual revenue of 6.93B with 6.66% growth.
Revenue (ttm) 
 7.18B
Revenue Growth 
 +7.84%
P/S Ratio 
 31.07
Revenue / Employee 
 n/a
Employees 
 n/a
Market Cap 
223.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 6.93B | 432.62M | 6.66% | 
| Dec 31, 2023 | 6.50B | -90.76M | -1.38% | 
| Dec 31, 2022 | 6.59B | -1.53B | -18.85% | 
| Dec 31, 2021 | 8.12B | 3.97B | 95.64% | 
| Dec 31, 2020 | 4.15B | 3.67M | 0.09% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Samsung Biologics | 5.03T | 
| Celltrion | 3.75T | 
| Yuhan | 2.17T | 
| SK Biopharmaceuticals | 620.28B | 
| PharmaResearch | 449.81B | 
| Sam Chun Dang Pharm. | 215.10B | 
| ALTEOGEN | 158.06B | 
| LigaChem Biosciences | 148.28B |